Cost-effectiveness of trastuzumab biosimilar combination therapy and drug wastage as first-line treatment for HER2-positive metastatic breast cancer

por Leung, John Hang, Tai, Yun-sheng, Wang, Shyh-Yau, Yip Fion, Hei-Tung, Tsung-chin, Ho, Chan, Agnes LF.
Publicado 2022